BVXV News and Press, BiondVax Pharmaceuticals Ltd. From 01/04/23

BiondVax has released statistically significant results showing efficacy of its inhaled NanoAb as anti-COVID-19 therapy, as part of a preclinical proof-of-concept animal study The study was conducted in collaboration with the world-renowned institutes Fraunhofer Institute for Toxicology and Exp...

BiondVax Pharmaceuticals (NASDAQ: BVXV) , a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has published a letter from CEO Amir Reichman. The letter provides an overv...

JERUSALEM, Dec. 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products for the treatment of infectious and autoimmune diseases, ...

BiondVax (NASDAQ: BVXV) is focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. “BiondVax is developing a pipeline of nanosized antibody (‘NanoAb’) therapies addressi...

Macular degenerative disease is one of the leading causes of vision loss in older adults across the world. It is characterized by loss of central vision as part of the inner layers of the retina that facilitate clear vision steadily break down. Around 20 million adults in America are estimated ...

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Aegis Capital Corp. , which is dedicated to providing corporate finance, strategic...

Asthma is a common condition that causes an individual’s airways to swell and narrow , resulting in breathing difficulties, coughing and breathlessness. During childhood, the disease is more prevalent and severe in boys. Following puberty, however, asthma becomes more common and severe in...

NEW YORK, NY / ACCESSWIRE / December 21, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV). About BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical...

BiondVax (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced the closing of its underwritten public offering with gross proceeds t...

JERUSALEM, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV )(“Company”), a biotechnology company, which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treat...